Upgrade to SI Premium - Free Trial

Beam Therapeutics Inc. (BEAM)

25.67 +1.17 (4.78%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/9/26)

Latest Headlines

Form 4 Beam Therapeutics Inc. For: Oct 01 Filed by: Cavanagh Bethany J October 2, 2026 4:05 PM - SEC Filing Form 4 Beam Therapeutics Inc. For: Sep 24 Filed by: Ciaramella Giuseppe September 25, 2026 4:05 PM - SEC Filing Beam Therapeutics shares updated BEAM-302 trial data at ERS 2026 September 8, 2026 6:00 AM - StreetInsider Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 September 8, 2026 6:00 AM - StreetInsider Beam Therapeutics names Eric Foster as chief commercial officer September 1, 2026 7:00 AM - StreetInsider Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer September 1, 2026 7:00 AM - StreetInsider Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences August 31, 2026 7:00 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM) August 25, 2026 6:58 AM - StreetInsider Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: ARK Investment Management LLC August 14, 2026 2:56 PM - SEC Filing Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C. August 13, 2026 5:14 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM) August 10, 2026 6:43 AM - StreetInsider Beam Therapeutics Inc (BEAM) PT Raised to $240 at JPMorgan August 5, 2026 8:11 AM - StreetInsider Form 10-Q Beam Therapeutics Inc. For: Jun 30 August 4, 2026 7:14 AM - SEC Filing Beam, Inc. (BEAM) Misses Q2 EPS by 8c August 4, 2026 7:14 AM - StreetInsider Form 8-K Beam Therapeutics Inc. For: Aug 04 August 4, 2026 7:09 AM - SEC Filing Beam Therapeutics posts Q2 loss, doses first patient in BEAM-302 trial August 4, 2026 7:00 AM - StreetInsider Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) August 4, 2026 7:00 AM - StreetInsider Form 4 Beam Therapeutics Inc. For: Jul 27 Filed by: Simon Amy July 29, 2026 4:05 PM - SEC Filing Form 144 Beam Therapeutics Inc. Filed by: Simon Amy July 27, 2026 4:05 PM - SEC Filing Beam Therapeutics to present BEAM-302 trial data at ERS 2026 July 23, 2026 7:00 AM - StreetInsider Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congres July 23, 2026 7:00 AM - StreetInsider TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential' July 8, 2026 12:30 PM - StreetInsider BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff July 8, 2026 11:32 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM) July 7, 2026 7:03 AM - StreetInsider Full Article List